The VAD chemotherapy regimen plus a G-CSF dose of 10 lg/kg is as effective and less toxic than high-dose cyclophosphamide plus a G-CSF dose of 5 lg/kg for progenitor cell mobilization: results from a monocentric study of 82 patients A study was conducted to compare the efficiency and toxicity of two peripheral blood stem cell (PBSC) mobilization procedures for newly diagnosed patients with multiple myeloma. Patients from group 1 (n ¼ 51) were treated by high-dose cyclophosphamide (HD-CY) plus G-CSF (5 lg/kg/day), and the second group (n ¼ 31) by VAD regimen plus G-CSF administration (10 lg/kg/day). Successful mobilization, defined by a minimal count of 2.5 Â 10 6 CD34 þ cells/kg collected, was achieved in 96 and 90% of patients in groups 1 and 2, respectively (P ¼ 0.15). The mean peripheral blood CD34 þ cells concentration and the mean CD34 þ cells/kg collected were higher in group 2 than in the group 1 (P ¼ 0.05). The mean number of leukaphereses necessary to collect a count of 2.5 Â 10 6 CD34 þ cells/kg was reduced in group 2 compared to group 1. Adverse events, blood products consumption and time spent in the hospital were significantly greater after HD-CY. In conclusion, VAD plus a G-CSF dose of 10 lg/kg administration seems preferential to HD-CY plus a G-CSF dose of 5 lg/kg for PBSC collection because of equivalent or better efficiency in stem cell mobilization, strong favorable toxicity profile and reduced cost.
Introduction
Over the last few years, high-dose chemotherapy with autologous hematopoietic progenitor cell support has been increasingly used for the treatment of multiple myeloma (MM). 1, 2 The optimal count for CD34 þ cells necessary for short-and long-term hematologic reconstitution is not well characterized, but the minimal count of 2.5 Â 10 6 CD34 þ cells/kg is commonly recognized to ensure hematologic reconstitution for a majority of patients. 4 However, it has been reported that high CD34 þ cell counts infused after myeloablative regimens decreases hematologic toxicity and may improve the patients' quality of life. 5 Moreover, the superiority of tandem autotransplantation for patients with MM has also been suggested. [1] [2] [3] Both observations lend support to the collection of a maximal amount of CD34 þ cells within a reasonable number of leukaphereses (LK). Factors affecting PBSC mobilization in patients with MM, such as age, prior alkylating agent administration, have been extensively reported. [6] [7] [8] However, the choice for the best strategy to collect a large amount of PBSC with reduced toxicity from patients with MM is still controversial.
High-dose cyclophophamide (HD-CY) plus G-CSF administration appears to be the most frequent regimen employed in such a situation. This strategy is very efficient for CD34 þ cells mobilization and may help to treat patient with MM, but is associated with several side -effects such as nausea, emesis, neutropenic fever, sepsis and hemorragic cystitis with mortality rates of 1-2%, and needs supportive care. [9] [10] [11] The VAD regimen is a polychemotherapy commonly used for patients with MM. [12] [13] Combined to G-CSF, VAD administration displays the potential to mobilize PBSC with a theoretically reduced toxicity as compared to HD-CY.
To evaluate efficiency and toxicity of both strategies for PBSC mobilization, we conducted a retrospective comparative monocentric study in patients with MM treated either by VAD plus a G-CSF dose of 10 mg/kg or by HD-CY plus a G-CSF dose of 5 mg/kg. To our knowledge, this is the first comparative report of these two mobilizing regimens in MM patients.
Patients and methods
Between January 1996 and December 2004, 82 consecutive patients with MM were admitted in our division for PBSC mobilization. Before 2003, all patients usually underwent HD-CY for stem cells mobilization according to standard procedures based on our current trials and habits during this period. Between 2003 and 2004, 31 patients received the VAD regimen for PBSC mobilization instead of HD-CY to assess the efficacy and toxicity of such a strategy. All these procedures for chemotherapy and G-CSF administrations for PBSC mobilization were realized in accordance with the currents medical practices. All patients were registered for age, stages for Durie and Salmon criteria, renal function and prior chemotherapy ( Table 1 ). All patients were mobilized following the diagnosis or after a first-line therapy consisting of prior VAD regimens, whose number varied among patients. The median numbers of previous course of VAD received before the chemotherapy used for PBSC mobilization are indicated in Table 1 . Patients previously treated by extensive radiotherapy (pelvic, vertebral) and/or alkylating agents were excluded from this study. All patients studied signed informed consent before PBSC mobilization. Two and one patients had previously received local radiotherapy (shoulder, leg) in groups HD-CY and VAD, respectively.
Patients from group 1 were hospitalized for 3 consecutive days and received HD-CY at the daily dose of 60 mg per kg body weight for 2 consecutive days (a total dose of 120 mg per kg body weight). For urothelial protection, all patients were given uromitexan. Hyperhydration (3 l/m 2 ) was given over 48 h starting 6 h before CY administration and was associated with urine alkalinization. Day 1 was defined as the first day of HD-CY administration. Patients were discharged from the hospital and received ambulatory G-CSF administration at a daily dose of 5 mg/kg starting from day 8, until white blood cell (WBC) recovery and completion of LK.
All patients from group 2 received the current VAD chemotherapy regimen (doxorubicin 9 mg/m 2 /day, vincristine 0.4 mg/day and dexamethasone 40 mg/day) administered from days 1 to 5.
11,12 G-CSF was introduced at a daily dose of 10 mg/kg from days 10 to day 15.
All chemotherapy doses were calculated according to the ideal body weight. Entire G-CSF vials were injected to patients. So, the exact G-CSF doses administered were not always strictly as wished owing to the limitations in the different concentrations in commercially available vials. Lenograstim34 (Chugai-Rhoˆne-Poulenc, Montrouge, France) and FilMontrage, grastim30 and 48 (Amgen, Neuilly-sur-Seine, France) were administered without preferential use. The choice depended on various habits of the different physicians during the same period of time. The median exact G-CSF doses administered for each group of patients are indicated in Table 2 .
Assessment of PBSC collection
Quantification of venous CD34 þ cell concentration was performed when WBC recovery reached 5 Â l0 9 /l following HD-CY administration. In the 'VAD group', owing to the frequent absence of significant decrease in WBC following chemotherapy, venous CD34 þ cell concentration was systematically performed on the fifth day of G-CSF administration.
Leukapheresis was initiated if the CD34 þ cell concentration reached 10/ml. If three CD34 tests (o10/ml) performed every other day were negative despite continued administration of G-CSF, stem cell harvesting was not performed. The quantity of harvested stem cells was evaluated through CD34 þ cell quantification performed as previously described on the product of the LK for each patient and at the end of the procedure if two or more LK had been performed. Briefly, CD34 þ cells were quantified using fluorescence analysis; 1 Â 10 6 mononuclear cells were incubated for 30 min at 41C with the fluorescein isothio- Table 1 Pre-mobilization characteristics of patients 4 Successful PBSC collection was defined by a minimal number of 2.5 Â 10 6 CD34 cells/ kg. The number of LK necessary to obtain the count of at least 2.5 Â 10 6 CD34 þ cells/kg was recorded for each patient.
Infectious events, the need for hospitalization, blood products and total G-CSF consumption were recorded for each patient. Intravenous antibiotics were administered at hospital admission if patients presented with a persistent fever despite 2 consecutive days of oral antibiotics. Irradiated prophylactic single donor platelet and packed red blood cell transfusions were administered when the platelet count was less than 20 Â 10 9 /l and the hemoglobin level less than 8 g/dl, respectively.
Statistical analysis
Categorical variables were summarized as count and percentage, whereas numerical variables were summarized as median and inter-quartile range. Fisher's exact test was used to compare the distribution of categorical variables between treatment groups. Tests for significance between group differences in numerical variables were performed using non-parametric Wilcoxon rank sum test. The significance level of P-values was set to 0.05. All computation analyses were performed using the statistical software named 'R' (http://www.r-project.org), which is available as Free Software under the terms of the Free Software Foundation's GNU General Public License version 2.01 for Microsoft Windows.
Results
Patient characteristics are shown in Table 1 . There was no difference in the age, stage of disease or renal function between the two groups. However, the median number of previous courses of VAD administered before the mobilization chemotherapy was higher in patients belonging to group 2 than group 1. The mobilization efficiency was equivalent between the two groups ( Table 3 ). The same proportion of patients achieved a successful PBSC mobilization in both groups. Patients from group 2 (VAD þ G-CSF 10 mg/kg) presented a higher but not significant PB CD34 þ cell mobilization than patients from group 1 (HD-CY þ G-CSF 5 mg/kg), but the mean yield of harvested CD34 þ cells was significantly higher for group 2 than for group one. Moreover, the mean number of LK necessary to perform the stem cell collection was reduced in group 2 compared to group 1.
The HD-CY group was associated with higher toxicity as assessed by the frequency of severe thrombocytopenia, neutropenia, fever and need for supportive care (Table 4) . No patient from the VAD group needed hospitalization, whereas one-third of the patients in the HD-CY group required hospitalization from 1 to 5 days to ensure the supportive care.
Discussion
Many strategies for PBSC mobilization have been reported for patients with MM. High-dose cyclophosphamide (5-7 g/m 2 ) is commonly used for PBSC mobilization. [9] [10] [11] 14 
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This strategy is known to be effective, but is associated with significant toxicity and a frequent need for intensive supportive care. This is the first study comparing the efficacy and toxicity of either VAD or HD-CY regimens in combination with G-CSF as mobilizing therapy in newly diagnosed patients with MM. As the VAD chemotherapy regimen is commonly used in newly MM diagnosed patients, especially for the younger patients eligible for stem cell transplantation, we try to combine both chemotherapy administration and PBSC collection within the same schedule. Despite a limited impact on bone marrow cells and a low PB WBC decrease, the VAD regimen may have potential for PBSC mobilization. However, the reduced dose of doxorubicin used in such regimen may be insufficient to mobilize enough PBSC. For this reason, similar to steadystate stimulation by growth factor alone, we used higher G-CSF dose (10 mg/kg/day) after VAD administration than the dose of 5 mg/kg/day employed after HD-CY. Previous therapy may have a major negative impact on stem cell mobilization. 7 Thus, we selected for this comparative study two groups of patients without previous administration of alkylating-agent-based regimens and/or extensive radiotherapy, which may induce severe stem cell toxicity. In our study, all patients were naive for chemotherapy or had received only a limited number of VAD regimens before PBSC mobilization. The two groups of patients were well balanced for mean age, isotype distribution, stages of the disease and renal function impairment. Patients from the HD-CY group had received a smaller mean number of VAD courses before the mobilization procedure than group 2 patients. However, this difference was very narrow and because of the low stem cell toxicity of such a regimen probably may not unlikely to affect the potential for PBSC mobilization.
This analysis shows that both mobilization procedures are efficient for the large majority of treated patients with a similar proportion of success (Table 3) . However, within the limits of the study, the VAD regimen plus 10 mg/kg/day of G-CSF allowed a better PBSC collection with less number of LK than HD-CY plus 5 mg/kg/day administration despite a higher number of previous course of chemotherapy administered in the VAD group (than HD-CY group). Of course, one cannot exclude that the use of higher dose of G-CSF following HD-CY regimen would allow a stronger PBSC mobilization, thereby reducing the number of LK in a similar proportion to the VAD group. Moreover, owing to the higher toxicity of HD-CY, highdose G-CSF would probably not significantly decrease the incidence of serious complications requiring hospitalization. Probably, the application of higher doses of G-CSF in the VAD group than in the HD-CY group is a major factor leading to adequate or may be even superior stem cell collection in this group of patients.
Recent ) to DCEP regimen (dexamethasone, cyclophophamide, etoposide, cisplatin), both followed by G-CSF (5 mg/kg/day) administration, and concluded that DCEP was a bettertolerated and more effective regimen than HD-CY for PBSC mobilization in MM patients. Growth factor alone can also mobilize a sufficient number of CD34 þ cells for a majority of MM patients, but controlled studies suggest that CY plus GM-CSF or G-CSF is more effective in stem cell mobilization than G-CSF alone. [19] [20] [21] In our study, the VAD plus G-CSF mobilization regimen was well tolerated, with neither admission for febrile neutropenia nor blood transfusion requirement, whereas HD-CY regimen was associated with a significant higher incidence of adverse effects requiring hospitalization, such as infections, fever, cytopenias and frequent transfusion support (Table 4) . Moreover, HD-CY administration requires a systematic hospitalization for 3 consecutive days, whereas VAD could be administered in an ambulatory fashion for a large majority of patients, thereby allowing less discomfort and providing subsequent savings in terms of economical cost.
Ideally, the mobilization regimen for patients with MM would provide additional antineoplastic effect. Both VAD and HD-CY regimens allow responses in first front-line therapy in such indication. However, an added benefit on the prognosis of MM patients conferred by an additional course of HD-CY following a sequence of VAD is not demonstrated. No comparative studies are available to demonstrate an ideal chemotherapy before PBSC collection that would allow better tumor cell reduction in apheresis products. Moreover, of such tumor cell contamination may have no influence on the global prognosis of patients following autograft, as suggested by trials using in vitro purge. 22, 23 To conclude, VAD plus a standard G-CSF dose of 10 mg/ kg/day is as effective as HD-CY followed by lower dose of G-CSF (5 mg/kg/day) in newly diagnosed patients for PBSC mobilization and collection. Moreover, VAD regimen is associated with significantly less toxicity and allows outpatient management with reduced cost. 
